Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies Marianne HolmAnne TjønnelandNiels Kroman Review 10 July 2014 Pages: 461 - 475
Leptomeningeal disease and breast cancer: the importance of tumor subtype Sausan AbouharbJoe EnsorAmal Melhem-Bertrandt Review 20 July 2014 Pages: 477 - 486
Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer Meiyun FanAarti SethuramanLawrence M. Pfeffer Preclinical study 08 July 2014 Pages: 487 - 502
Association study of susceptibility loci with specific breast cancer subtypes in Chinese women Bo ZhangYang LiZhen-dong Chen Preclinical study 10 July 2014 Pages: 503 - 514
RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase Hong HuJun WangSeema A. Khan Preclinical study 10 July 2014 Pages: 515 - 523
Metabolic differences in breast cancer stem cells and differentiated progeny Erina VlashiChann LagadecFrank Pajonk Preclinical study 10 July 2014 Pages: 525 - 534
RETRACTED ARTICLE: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression Zhongxing LiangXuehai BianHyunsuk Shim Preclinical study 17 July 2014 Pages: 535 - 542
Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells Anuradha SehrawatKozue SakaoShivendra V. Singh Preclinical study 20 July 2014 Pages: 543 - 555
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases Carey AndersAllison M. DealLisa A. Carey Clinical trial Open access 08 July 2014 Pages: 557 - 566
Platinum-based chemotherapy in triple-negative advanced breast cancer Cynthia Villarreal-GarzaDaniel KhalafRebecca Dent Clinical trial 08 July 2014 Pages: 567 - 572
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer Elisabetta MunzoneVincenzo BagnardiMarco Colleoni Clinical trial 10 July 2014 Pages: 573 - 582
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival Christian B. van der PolMark E. SchweitzerArash Jaberi Clinical trial 10 July 2014 Pages: 583 - 589
Choosing relevant endpoints for older breast cancer patients in clinical trials: an overview of all current clinical trials on breast cancer treatment N. A. de GlasM. E. HamakerE. Bastiaannet Epidemiology 09 July 2014 Pages: 591 - 597
Long-term cognitive function change among breast cancer survivors Ying ZhengJianfeng LuoQi Dai Epidemiology 09 July 2014 Pages: 599 - 609
Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women Catherine S. BerkeyRulla M. TamimiGraham A. Colditz Epidemiology 18 July 2014 Pages: 611 - 618
Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia Sébastien CouraudSophie Dell’AnielloLaurent Azoulay Epidemiology 20 July 2014 Pages: 619 - 626
Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases Hanna DillekåsMonica TransethOddbjørn Straume Epidemiology Open access 20 July 2014 Pages: 627 - 636
Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States Rohini K. HernandezDavid QuachAlexander Liede Epidemiology 23 July 2014 Pages: 637 - 646
Central adiposity after breast cancer diagnosis is related to mortality in the Health, Eating, Activity, and Lifestyle study Stephanie M. GeorgeLeslie BernsteinRachel Ballard-Barbash Epidemiology 24 July 2014 Pages: 647 - 655
ERβ splice variant expression in four large cohorts of human breast cancer patient tumors Hallie WimberlyGang HanDavid L. Rimm Brief Report 10 July 2014 Pages: 657 - 667
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial Vakaramoko DiabyGeorges AdunlinRima Tawk Brief Report 14 July 2014 Pages: 669 - 673
